UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 121

Sortiert nach

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

The lancet oncology, 2017-03, Vol.18 (3), p.e143-e152

2017

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm

Nature reviews. Clinical oncology, 2020-11, Vol.17 (11), p.707-715

2020

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation

Clinical cancer research, 2019-02, Vol.25 (3), p.946-956

2019

Link zum Volltext

Verfügbarkeit prüfen

Current standards and new innovative approaches for treatment of pancreatic cancer

European journal of cancer (1990), 2016-04, Vol.57, p.10-22

2016

Link zum Volltext

Verfügbarkeit prüfen

Are G3 ENETS neuroendocrine neoplasms heterogeneous?

Endocrine-related cancer, 2013-10, Vol.20 (5), p.649-657

2013

Link zum Volltext

Verfügbarkeit prüfen

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer

PloS one, 2018-10, Vol.13 (10), p.e0204490-e0204490

2018

Link zum Volltext

Verfügbarkeit prüfen

Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973)

BMC cancer, 2018-08, Vol.18 (1), p.787-787, Article 787

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of immunotherapy (IO) on primary renal tumor in metastatic renal cell cancer (mRCC)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.649-649

2019

Link zum Volltext

Verfügbarkeit prüfen

CT Texture Analysis Challenges: Influence of Acquisition and Reconstruction Parameters: A Comprehensive Review

Diagnostics (Basel), 2020-04, Vol.10 (5), p.258

2020

Link zum Volltext

Verfügbarkeit prüfen

CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers

Journal for immunotherapy of cancer, 2022-02, Vol.10 (2), p.e004012

2022

Link zum Volltext

Verfügbarkeit prüfen

Epidemiological Study to Assess the Prevalence of Lung Cancer in patients with smoking-associated atherosclerotic cardiovascular diseases: PREVALUNG study protocol

BMJ open, 2022-12, Vol.12 (12), p.e067191-e067191

2022

Link zum Volltext

Verfügbarkeit prüfen

Interest of diffusion-weighted echo-planar MR imaging and apparent diffusion coefficient mapping in gynecological malignancies: A review

Journal of magnetic resonance imaging, 2011-05, Vol.33 (5), p.1020-1027

2011

Link zum Volltext

Verfügbarkeit prüfen

Dual-energy CT angiography reveals high prevalence of perfusion defects unrelated to pulmonary embolism in COVID-19 lesions

Insights into imaging, 2021-02, Vol.12 (1), p.24-24, Article 24

2021

Link zum Volltext

Verfügbarkeit prüfen

Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper

Frontiers in oncology, 2022-01, Vol.11, p.800547-800547

2022

Link zum Volltext

Verfügbarkeit prüfen

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer

Cancers, 2020-12, Vol.12 (12), p.3758

2020

Link zum Volltext

Verfügbarkeit prüfen

Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC

Therapeutic advances in medical oncology, 2022, Vol.14, p.17588359211058391-17588359211058391

2022

Link zum Volltext

Verfügbarkeit prüfen

Accuracy of Diffusion-Weighted Echo-Planar MR Imaging and ADC Mapping in the evaluation of residual Cervical Carcinoma after radiation therapy

Gynecologic oncology, 2011-10, Vol.123 (1), p.110-115

2011

Link zum Volltext

Verfügbarkeit prüfen

Advances in oncological treatment: limitations of RECIST 1.1 criteria

The quarterly journal of nuclear medicine and molecular imaging, 2018-06, Vol.62 (2), p.129

2018

Link zum Volltext

Verfügbarkeit prüfen

Tumour burden and efficacy of immune-checkpoint inhibitors

Nature reviews. Clinical oncology, 2022-02, Vol.19 (2), p.75-90

2022

Link zum Volltext

Verfügbarkeit prüfen

18F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data

EJNMMI research, 2020-07, Vol.10 (1), p.88-88, Article 88

2020

Link zum Volltext

Verfügbarkeit prüfen

Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?

Journal of thoracic oncology, 2019-03, Vol.14 (3), p.328-331

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-10, Vol.36 (28), p.2872-2878

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 121

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(112)

Publikationsform

Artikel
(118)
Berichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(75)
Life Sciences & Biomedicine
(74)
Humans
(55)
Oncology
(53)
Female
(29)
Middle Aged
(28)
Male
(27)
Life Sciences
(26)
Adult
(21)
Aged
(20)
Imaging
(18)
Radiology, Nuclear Medicine & Medical Imaging
(17)
Patients
(15)
Prognosis
(15)
Immunotherapy
(14)
Tumors
(14)
Lung Cancer
(13)
Medicine
(13)
Medicine & Public Health
(13)
Metastasis
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm

Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation

Current standards and new innovative approaches for treatment of pancreatic cancer

Are G3 ENETS neuroendocrine neoplasms heterogeneous?

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer

Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973)

Effect of immunotherapy (IO) on primary renal tumor in metastatic renal cell cancer (mRCC)

CT Texture Analysis Challenges: Influence of Acquisition and Reconstruction Parameters: A Comprehensive Review

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)

CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers

Epidemiological Study to Assess the Prevalence of Lung Cancer in patients with smoking-associated atherosclerotic cardiovascular diseases: PREVALUNG study protocol

Interest of diffusion-weighted echo-planar MR imaging and apparent diffusion coefficient mapping in gynecological malignancies: A review

Dual-energy CT angiography reveals high prevalence of perfusion defects unrelated to pulmonary embolism in COVID-19 lesions

Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper

Standardised lesion segmentation for imaging biomarker quantitation: a consensus recommendation from ESR and EORTC

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer

Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC

Accuracy of Diffusion-Weighted Echo-Planar MR Imaging and ADC Mapping in the evaluation of residual Cervical Carcinoma after radiation therapy

Advances in oncological treatment: limitations of RECIST 1.1 criteria

Tumour burden and efficacy of immune-checkpoint inhibitors

18F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data

Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy

Suchergebnisse filtern